<SEC-DOCUMENT>0001214659-20-003193.txt : 20200406
<SEC-HEADER>0001214659-20-003193.hdr.sgml : 20200406
<ACCEPTANCE-DATETIME>20200406060242
ACCESSION NUMBER:		0001214659-20-003193
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200406
DATE AS OF CHANGE:		20200406
EFFECTIVENESS DATE:		20200406

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		20775636

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SISTERS OF ST FRANCIS OF PHILADELPHIA
		CENTRAL INDEX KEY:			0001519001
		IRS NUMBER:				231352545
		STATE OF INCORPORATION:			PA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		606 SOUTH CONVENT ROAD
		CITY:			ASTON
		STATE:			PA
		ZIP:			19014
		BUSINESS PHONE:		610-558-7661

	MAIL ADDRESS:	
		STREET 1:		606 SOUTH CONVENT ROAD
		CITY:			ASTON
		STATE:			PA
		ZIP:			19014
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>r43200px14a6g.htm
<DESCRIPTION>PFE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">1</P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="sisters_logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Lead Filer:</B></TD><TD><B>Sisters of St. Francis of Philadelphia</B></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>609 S. Convent Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>Aston, PA 19014</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in"><B>tmccaney@osfphila.org</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vote FOR Proposal #7 to Require an Independent
Chair at<BR>
Pfizer, Inc. [NYSE: PFE)<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>i</SUP></FONT> Meeting Date: April 23,
2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Fellow Pfizer Shareholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We urge you to vote FOR Proposal #7 (the &ldquo;Proposal&rdquo;)
asking the Pfizer (PFE) board to require an independent director as chair at the May 5, 2020 Annual Meeting. This proposal is not
intended as a referendum on Dr. Albert Bourla&rsquo;s leadership as CEO or fitness as a director, but solely on his continued service
as chair. We believe a structure where the CEO runs the business and is accountable to a board led by an independent chair is in
the best interests of the company&rsquo;s shareholders for the following reasons:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Eliminates Structural Conflicts of Interest in Dual Role</U>. The management of a complex global pharmaceutical company
is a full-time job. It is unrealistic &ndash; and needlessly complicated -- to expect one person to perform well as CEO on top
of his or her responsibilities for providing rigorous board oversight. An independent board chair eliminates the structural conflicts
of interest caused by the CEO essentially being his or her own boss, and clarifies where the authority of the CEO ends and responsibility
of the independent board members begins.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><U>Significant Governance Concern Resulting from Board Failure to Oversee Material Risks</U>. In light of rising material legal,
regulatory, financial and reputational risks, controversies and legal challenges facing the company (as described in more detail
below), we are concerned that the board is not providing sufficiently robust oversight of the company&rsquo;s culture, risk management
and internal controls. Adopting best governance practices, including an independent board chair, should help promote that necessary
oversight.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that independent board leadership is particularly
important at companies in the pharmaceutical industry, including PFE. Given the business risks created by high drug prices and
compliance problems, we believe that strong, independent board oversight would be useful as a check against insular corporate thinking.
PFE, along with two other large U.S. pharmaceutical companies, announced on January 1, 2020 that it would again hike the price
of vital medicines. PFE alone raised prices by more than 9% on over 40 pharmaceutical products for 2020, including price hikes
of about 5.6% on about 27% of the drugs it sells in the United States. (MarketWatch, 2020)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border: Black 1pt solid; width: 100%"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>This is not a proxy solicitation, to vote your proxy. Please
DO NOT send us your proxy card, as it will not be accepted.</B></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These price hikes have generated substantial media attention,
which raise concerns about reputational and financial harm to the company and its shareholders. In our opinion, repeated price
increases are unsustainable, both as a business strategy and for the broader health care system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In its statement in opposition to the Proposal, PFE justifies
combining the roles of chair and CEO by touting the designation of a Lead Independent Director. PFE states, &ldquo;The position
of Lead Independent Director at Pfizer comes with a clear mandate, significant authority and well-defined responsibilities under
a Board-approved charter.&rdquo; The goal, apparently, is to emulate a Board with separate members filling the Chair and CEO roles.
According to Pfizer&rsquo;s Charter of the Lead Independent Director, the LID &ldquo;Serves as liaison between the independent
Directors and the Chairman and CEO&rdquo;. However, this liaison function is only made necessary by combining the chair and CEO
positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe an independent lead director is not an adequate substitute
for an independent board chairman. According to the EY Center for Board Matters, a lead independent director &ldquo;do[es] not
command the same authority as a board chair.&rdquo; In PWC&rsquo;s 2019 survey of over 700 directors, 57% of directors who sit
on a board with a combined chair/CEO say it is difficult to voice dissent. When the chairman and CEO are the same person, there
is a greater risk that important questions will not get asked.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. boards are increasingly recognizing the need to have an
independent board chair. According to the 2019 U.S. Spencer Stuart Board Index, the number of S&amp;P 500 companies with independent
board chairs has more than doubled over the past decade, to now include one-third of the companies.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>ii</SUP></FONT>
Among the companies listed in the Biotechnology/Pharmaceutical sectors, seven of 18 have truly independent chairs, including such
companies as Biogen Idec, Regeneron Pharmaceuticals, Perrigo Company and Nektar Therapeutics.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>iii</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vote FOR Proposal #7 to require an independent chair at Bristol-Myers
Squibb.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">An independent chairman is vital to ensure that tough questions
of strategy, governance, compliance and risk are being adequately discussed and independently overseen at the board level. By voting
&ldquo;FOR&rdquo; Proposal 7, you can send a message to the board of directors on the importance of independent board leadership.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please contact Tom McCaney at 610-558-7764/tmccaney@osfphila.org.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="tommccaney_sig.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tom McCaney</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Associate Director, Corporate Social Responsibility</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sisters of St. Francis of Philadelphia</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On behalf of co-filers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nicole Lee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lead ESG Analyst</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border: Black 1pt solid; width: 100%"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>This is not a proxy solicitation, to vote your proxy. Please
DO NOT send us your proxy card, as it will not be accepted.</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Miller/Howard Investments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Donna Meyer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director of Shareholder Advocacy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Dignity Health</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>i</SUP> <U></U> Eli Lilly and
Company (LLY), Bristol-Myers Squibb Company (BMY), AbbVie (ABBV), Pfizer Inc. (PFE), and Johnson &amp; Johnson (JNJ)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U></U>Amgen Inc. (AMGN) and Gilead Sciences,
Inc. (GILD)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>ii</SUP><I> See</I> &ldquo;2019 U.S. Spencer Stuart
Board Index&rdquo;, at 8-9 (https://www.spencerstuart.com/-/media/2019/ssbi-2019/us_board_index_2019.pdf).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>iii</SUP> <I>Id</I>., at 48-49.</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border: Black 1pt solid; width: 100%"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>This is not a proxy solicitation, to vote your proxy. Please
DO NOT send us your proxy card, as it will not be accepted.</B></P></TD></TR>
</TABLE>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>sisters_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sisters_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /[^**** "BBB@ HHHH **** "BBFLVT9]_I_C1?6W7<+VU>B'4C
M-M&3T'7V'K7D_P 2/C=\-/A1:F?QMXITS2KAX7FM-*$WVG6[]4S@66CVRRWT
MP=L(DODBW5F'G311[I%_/_6/CO\ M#_M+SW.A? OP;J7@WP3///;77C&]>ZL
M[AX5<*\MQXE46]EIC_O$FETSP_/?Z]%$DRQR2%X8I=J="<]7:$+7<Y:+ILMY
M;]-ODSYK-^*<LRJHL+%U<QS.II1RK+H/$XR<KQ2<X0O'#T[R7-4K.*2NXJ=F
ME]\:A\9?#/\ PL'3/AAH,B^(O&$_VB\UJSTZ>.2W\*Z+9*INM1\07>UHK.9I
M)[*TM=,!:_FN]1L?.CMK*?[<OKD4F]0=NW@<<^W0$ [?<@'IQSQ\I_LQ_LT6
M'P'L]=U.]U8>(O&GBZ.P.O:Q]E$45O#9)E--TZ1TCNI+8W#RW-S<W$<$M_,8
M)7MX$@AAB^L1P /2HJ*"E:#YDK>]_,[*[2Z'?DU7-:^#6(S?#PP>*KSG46"I
MRC4^IT;J-*C4JQ_C5N5>TK35HJ<W",5&*"BBBH/6"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH 9(BR+M8*1N1L,H891U=3ALC*LH93U5@&4A@#3
M@,#%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5%-,D$;RN0%C4NQ8[5"CDEF((4#J6;"J
M.6(4$B6N3\9^#=$\=Z%?^&?$:74^BZK"MOJ-I::IJND275N) Y@>]T:_TZ^%
MO,1LN;<7'D741,%S'+ TD;M6NN9M*^K2N[>2TU^9%1U%3FZ48SJJ+=.$Y.$)
M3M[JE-1FXQ;WDH2:6R9\ZM^W!^S;#X@U'P]=_$&VM)=.NEM#JSZ=K$_AV[E+
M".1K37K33[C3&@AN62S-S/<P6]Q=NL-C+=%E)]CT+XV_";Q- ESH/Q'\#ZG'
M(L+*MMXJT9[@"=5:+S+3[5]JA9]V%CEB20D'Y17R[K'_  3M_9]U,S>1<>-]
M$FEE#K-IFOV<KQ#8(Q$BZUI&KQ;=ID^8Q^;F><F0F0UQ>M?\$SOA1J*6\5A\
M1/B#:-$SM)+?/X<U"YF;,NPEK31]'C5H#-B-S"\B8 W[<*.N4,&[<M2LM%>\
M%Y7T3???FZ=;IGP$,;XE4:D_;9-PYC:?.W!8;,*V&FJ;>D9.OSIR2T<N5)[I
M'Z.PW]M<1I+#-%+%( T<L<BNCJ>C(RY#*1R"#@]JF,R 9!!'J3CV],]:_+^R
M_P""8'@.UN4D'Q7\:$)(DG[G3M%MI^&C_P"6\9,@\R"$6\@"A)5W,Z%BV?15
M_P""=7PFFM[>VU/Q]\7-3@C=6N+:;Q%H<=I=QHP?[.T:>&C<V\#OEI?LMW#,
MYDG'G!+B=9,W3PZVQ#:NM/92ND[=>:UUJ>G3S7C"5E/A3!PULW_K#1:6BV2P
M%VKWUU_ ^X=3\4Z!HQ0:OK&DZ89"/+&H:G966\$,<I]JFAW<(V,==CX^[SY#
MX@_:B^ OAF*674OBAX1G\IID:+0]5C\37(E@D6*: V_AQ=5E6XB=@LENRB9,
MKNC&3M\MTW]@C]G#3VWW7AK5=7/V>*WVZAXCUF ;()#+"[2Z1>:5=RRQNSD2
M374N5D>,@Q"-(_7-&_9^^!G@Z)I](^&G@>P%L&F:]NM%L+VX@CPS32#4-46Z
MN($V-(9"LZ1E2WF J6!26'6\JL_*,8QOHNK;MK=?"_(Z/:\75E?ZKD&71:LY
M5<;CLQG!O[4H4L%@82:5]J\8WLMO>?@UU^VK:>*;EM,^#7PA^)?Q.N]Q87T&
MFR:-H(MT=%EN1J:0ZI(J1@RJ8[ZVTOS9EAMQ/&MU'.N5>Z#^VE\5\1:CK_A3
MX(^'[M09;;1&>[\4I%)<,I;[5:W6K2?;/L:O-LMM?T#R6E@MCY+&2Y@[WQO^
MVC\$/ UU#H.C7.J^/M<(,5MHWP^T^+5T BB9PL=^TUGI<T:HF,:;=7SQJ"6B
M5%8KY?/^U5\?O%5Q!8?#[]EGQCITM_<&WLM;\;VFOQ:-_I+F.SNKF2+0]+LX
M+5&9+FYG.M&U$ <).[A=VT8R2YH4(P2UYJLDW]G^:W36W*_F?,XK'X"M.5',
M^+<PS22:4\!PS@Z]"BVVKTY5<MCC*_*[N/+4S"-T[.^J.Z\!_L*_"#P_*FL^
M-FU+XJ^)9YI;ZZU'QFZW&GS7TP/FSG28&47<<JL1/;Z[>:RDIP!Y<<5M#;_9
MMAI]KIEM!9V,$%I9VL$5M:VMK#';V]M;PHL<4,$,8"111QHB)'&JHJJ J@
M8OA.V\21:'IS>+KS2+SQ&\*RZM+H-C=V&CK<N69K?3K>^OM0NQ:VP98([BXN
M#/=+$)Y(H#)Y$745S5*DZC]^3E;:WP_)*RLNA]OE6497E="*R[+:6 52*G.*
MIQ^L2D]?]HJ\U2I5J)OWI3JU'S7]YML:% )8=3G/XG/I3J**S/6"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *J75J]R $NI[4AX6+P"(N5BF65X_WT<J*LZ*;>
M5U02K!+*89(K@0SP6Z* $ (ZG/\ ^H#^F?J:6BB@ HHHH **** "BBB@ HHH
MH **** "BBB@#+UG5['0M+U'6=4N[>PTS2K"\U+4+ZZ<16UG96-O+=7=W<2'
MB.WMH(I)IG/"1HS'@5^:'Q(_;/\ B'X\U-/!_P"S)X#U'7KR>:6W;Q;=Z7]M
MN=B( ;G2]#G"VUC;1F1)6OO$4L9&4@GTRT9Q=Q?I#XK\-V?B_P /:YX9U*2>
M/3O$.CZCHE^ULR)<BRU2SGL;KR'ECFC24P7#A&DBE0-C?'(N5.!X!^%W@GX9
MZ/#HG@S0;'1;.,()7@A#WU\Z+M^T:EJ$V^]O[I@3NGNII& .R,1QA4&]&=*%
MY5*?M))KEBW:&FMVMV[[:H^;SS 9[F=2CA<OS2.49>XR>-Q5"GSYE4;:4:.%
MG*\,.K*3E6:<[N*C9*5_S@T;]DS]IKXH3)K'QI^,^K: DRSF30].U6_UN[B-
MW<1O<+'IMA>Z?X4T?,"JF--EU"%9D0%"%/F>SZ1^Q!%X;A2\\*_'3XN^']?C
MPRWEIJEDFFLS<O#)I4=M&YM&WL'MC?%)2-\JS9"G[X "C I""<_-@?0?SIRQ
M55[<D5T481VZ+6__  3BPW O#]"*=6EC,;B-Y8O&YCC*^*YG\4HU?;1]DY7=
M_9*"MHK6/B'X:_%WXD^ _BS;_ ;XX7-EK]_K,'VWX?\ Q"TZWBLD\067E:A-
M!;ZU90B.""_E73;ZU>2V2,Q7]O';S"^CU&UU)_MY6RH8D8]0>.N.O^>:_.#]
MJV[%Q^TG^RIIUE&Z7UAXOT_4;^]B\M=NFWOBSP];V\,[,2S "QU;[,JH2KSS
M#H[ _??B/Q#I7A+POJ_B77+M++2- TZ[U;4KMR3Y%A8*]U<RA,AY76"-V2!#
MYDSXAB&YE%%:-_9344G5CJH]97MHK]?+17L7P[C*E*MQ%EV(Q,Z^&R/'TZ6'
MQ6(FYU(X6K@:.*E2Q%:;O4EAI.I%U):N'*I-RBV^4^*?Q7\*_"?P^^O>);L[
MIF^RZ+H]FOGZSX@U1U4P:9H]FA+W-S*2,DB."%,RW$J1 L?G2W^$WQ&_: 6V
MUOXZ:MJW@WP3>.MUI_P6\+Z@UF);5#N@C\?ZY!!;WNIRR(%-SID+PK;R/!+"
M=*U".>,<%^SG:ZI^T1\1_$O[17C>"=O#VBZC-X=^$GA^[,KVNG64,<5U+JIM
MY0+>6^MUNX(FOK<W,,^L'4)0\4FGV45I^BD4815QGC/ZD_X\ <#H..*)/V#Y
M8JU6UI2?V79:1OI=:IOOMMJL$I<41>.Q3FLCG-_V?E\9N$<PHPGR_7L>XI.M
M0K.+>'P?,J+HVGB(5)SM'C/"?P[\%^"+%-.\(>&]%\-V:!%,6CZ;:63R^6@C
M#7,\40FO)2H^>:[DGF<\O(U=DD*HH4=>K,>K'N3T&3UXX'0<5R?CGX@^#?AO
MI%MKGC?Q!IWAW3;[6M'\.:?-?RL)-2\0>(+V/3M#T/2[2%);S4]8U:^ECM=/
MTRPM[B\NI6Q'$461T\1T+]LK]FKQ-J_B?0M!^+WA34M4\#^.M"^&/CFTA;4P
M_@7XB^)M4L]$T#P+XX=[!;?P=XPUG5M1L-/TSPUXFFTK5KNZNX(8[8M*M<\I
MMOWI-MN^K;NWVO\ DO,^LHX>G1I\F'H0I4::LHTJ<:=."T224$HQUMHK7;[L
M^GP,#%+44<R.BMN0;AG&Y>,G@'GKTSC(SP"PP2\.AX#*3UX8&@L=13=Z<_.O
M&<_,.,=<\]N_I3@<\CD'D$=Z "BO!_'_ .TG\'?AIXXT/X8^*?&EE_PL[Q+H
M>I^*M ^%_AO2_$/COXGZQX4T>Z^Q:GXJL/ASX&TCQ%XTF\*Z?=M%8W_B==#.
M@V>HRQZ?<7Z7<L44GH_@3QYX4^)7A'PWX]\$:W8^(_!OC#0]-\2>&/$%@S_8
MM8T/5[6*^TW4+83)',8+NSFBGC+QHX1L2QQ2!HU+C::M=-7U5TU==UW7FCL:
M*;O3GYUXZ_,..W//'(/7THWJ<X93@@'D<$G !]"2< =2:!#J*9YB?WT]?O#U
MQZ^O'UXI2RCJRCKU('3@_D>OI1<->WF.HIN]!DEUP."=PXX!YY]"#]"#W% =
M#G#*< $X8< ]"?8XX/>@!U%-WK_>7H3U'0=3]!W/:E)P">!@9R>@^OM0 M%,
M\Q0/F=!U_B &!]3V[TN]#D[EPOWCN''UYX_&@!U%-$B,0%=6)&0 P)(]0 >G
MOTI'8JC,,9 XSG&?^ @G\ .>G'6@!]%?,EG^V#^SYJ?B7QYX4T7XAV?B;5_A
M9XVT3X;_ !,'@W0_%OC33/A[X\\0W%M:Z;X3\:^(?"WA_5O#GA?7$N+ZSBU>
MQUO5K*3PZ;F!_$ TR.>,U]*QS*XR64'G W*<CUZ].>O?K@9P$FGMJ-J2=FFG
MV::>NVGF344P.">&0KUX8$]/8X_^M3\TQ!17DGQI^.'PU_9Z\ :Y\5/B_P"(
M3X/^'OAIK$:]XIET?7M8L-'34KRUTVRFU&/P]IFKWEI:W&H7EM8K>2VHMUNK
MFV@9Q)/$'U_"OQ0\*^,?$'B'POI$FO1:YX6L-!U36K+7O!GC3PD8M.\3R:Y#
MHE]83^*M T>TUFUO+CPWKEM)/H]Q?I97.GR6]\;:66W6975[7UTT];V^^S'R
MRY>;E?+>W-;2ZY;J_=<R;\F>B45 EU;2LR1W$$CINWJDL;LNQMK;E5B5VM\K
M9 PW!P:?)-%%')+++'%%"C22R2.J1Q1HI9Y)'8A41%!9F8A54$D@"G<1)14$
MUU;6T3SW%Q!!!&-TDTTL<42+Q\SR.RHHY'+$#D>HJO)JNF0Q0SS:C8107+!;
M>:2\MTBG9@Q589&D"2L0CD!"Q(5B.%. -=[:%^BH)[JVMHI)[FX@MX8HWFEF
MGECBBCAC&9)9))&5$CC'+NQ"J.6(J&+4M/GLQJ,-_93:>T#7(OHKJ"2S-L@+
M/<"Z1S 8$4$M*'\M0"2P% %VBJ%EJFFZC UQ8:A8WL".8WFL[N"YA63"MY;2
M0R.BOL=&VE@VUU;&&&6V>L:1J,MW!I^J:=?3V$ODWT-G?6UU+93$L/*NXX)7
M>VERCCRY@C91AC*G!<#1HHS_ (UF7&MZ-:7UEI=UJ^F6VIZD)3IVG7%_:PWU
M^(0#,;*TDE6XNA$"#+Y$<GE@@MB@#3HK,U/6M'T2U-]K.K:9I%D)$B-YJ=_:
MV%J)9 62,W%W+%$)' )1-^Y@"0"!2:3KFBZ_;/>:%J^EZU9QS/;276DW]IJ-
MLEQ&J-) \]G+-$LT:R(SQ%@ZJZ%E 89+@:E%-=@B,Y!(568@*S'"@DX50S,>
M. JEB> ">*_.>X_X*M_L166F_&G6;[XD^.=.T;]G+Q]IWPR^.^L:I^SG^TQI
M>D_"CQEJUQ;6]C8>.-3OOA!#I^@:?)]LM)KCQ#?W47AW3[6[M;W4=5M;.YMY
MY4Y*/Q-+UT*C"4W:,7)Z;*^[LOO>B[GZ-45P'_"TOAS#IOAS5K[Q[X+L=-\7
MV,.I^$M0O/$VC65GXHTV>WT^YBU#P]/=7T<>KV<D.K:9*EQ8/<Q&+4;!M_\
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MZ_H_A36O&7A31_%/B$9T#PUJGB'2-/U_7 )?()T?1[N\AU'4QYW[G_0K:?\
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M787>M7L->UTA /6IY5S.6M[)>2LY._K[Q7/+V:I_94I3^<E!/_TB/W'X"/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@")XED96/5#E?8^OY<5+110 4444 %%%% !1110 4444 %%%% !1110
*4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tommccaney_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tommccaney_sig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,"XU /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #L
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M3_!7@V.P-CX2-_JX!X1^R/H?C_1_C;^TE%X_^-6H?&+Q;IGA[X&:#\6=D?\
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MJ7BKPY9^./$4LNGRZQJ7PD+^#&\1:IJWAKQ^VGVMG,LNA^"?&'CF^6RN+C]
=E5454485%"J!V51@#\ ,4ZB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
